Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23218912 | 0.88 | ELANE (0.45) | NLRP3PDGFRACDK5TYRO3HTR4 | |
| SCHEMBL492267 | 0.85 | PDGFRA (0.40) | NLRP3PDGFRACDK5TYRO3ELANE | |
| SCHEMBL498197 | 0.85 | ELANE (0.51) | NLRP3PDGFRACDK5TYRO3HTR4 | |
| SCHEMBL14817010 | 0.84 | KDM4E (0.42) | HTR4HPGDHCAR3HCAR2ELANE | |
| SCHEMBL492125 | 0.80 | PDGFRA (0.47) | PDGFRACDK5TYRO3ELANEMCL1 | |
| SCHEMBL26980324 | 0.79 | RBP4 (0.44) | HTR4HPGDRBP4 | |
| SCHEMBL24247729 | 0.79 | PDGFRA (0.41) | NLRP3PDGFRACDK5TYRO3ELANE | |
| SCHEMBL29805676 | 0.78 | HTR4 (0.55) | HTR4 | |
| SCHEMBL1832626 | 0.78 | HTR4 (0.55) | HTR4 | |
| Hydrochloric Acid SCHEMBL1405875 | 0.77 | HTR4 (0.54) | HTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | US | disclosed |
| EP-3292107-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016177658-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-10 | — | — | WO | disclosed |
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| CN-101448798-A | Compounds and methods for modulating FXR | LILLY CO ELI (US) | 2009-06-03 | — | — | CN | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148418-A1 | AMIDO-SUBSTITUTED CYCLOHEXANE DERIVATIVES | C1R, C9, C1S | NLRP3 972/4885PDGFRA 2707/4885CDK5 1900/4885 |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | NLRP3 2977/4885PDGFRA 3161/4885CDK5 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.